Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more
Jiangsu Kanion Pharmaceutical Co Ltd (600557) - Total Assets
Latest total assets as of September 2025: CN¥6.74 Billion CNY
Based on the latest financial reports, Jiangsu Kanion Pharmaceutical Co Ltd (600557) holds total assets worth CN¥6.74 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Kanion Pharmaceutical Co Ltd - Total Assets Trend (1999–2024)
This chart illustrates how Jiangsu Kanion Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Kanion Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Kanion Pharmaceutical Co Ltd's total assets of CN¥6.74 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.8% |
| Accounts Receivable | CN¥706.87 Million | 10.2% |
| Inventory | CN¥540.27 Million | 7.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥359.45 Million | 5.2% |
| Goodwill | CN¥58.99 Million | 0.9% |
Asset Composition Trend (1999–2024)
This chart illustrates how Jiangsu Kanion Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Kanion Pharmaceutical Co Ltd's current assets represent 52.1% of total assets in 2024, a decrease from 80.4% in 1999.
- Cash Position: Cash and equivalents constituted 31.8% of total assets in 2024, up from 16.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
Jiangsu Kanion Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Kanion Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jiangsu Kanion Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Jiangsu Kanion Pharmaceutical Co Ltd generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Jiangsu Kanion Pharmaceutical Co Ltd generates $5.67 in net profit.
Jiangsu Kanion Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 2.60 | 1.70 |
| Quick Ratio | 1.73 | 2.22 | 1.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.65 Billion | CN¥ 2.29 Billion | CN¥ 1.19 Billion |
Jiangsu Kanion Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Kanion Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | CN¥6.91 Billion |
| Market Capitalization | $653.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Kanion Pharmaceutical Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jiangsu Kanion Pharmaceutical Co Ltd's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jiangsu Kanion Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual total assets of Jiangsu Kanion Pharmaceutical Co Ltd from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.91 Billion | -2.96% |
| 2023-12-31 | CN¥7.12 Billion | +4.73% |
| 2022-12-31 | CN¥6.80 Billion | +12.92% |
| 2021-12-31 | CN¥6.02 Billion | -1.64% |
| 2020-12-31 | CN¥6.12 Billion | +0.13% |
| 2019-12-31 | CN¥6.11 Billion | +9.06% |
| 2018-12-31 | CN¥5.60 Billion | +3.88% |
| 2017-12-31 | CN¥5.39 Billion | +14.03% |
| 2016-12-31 | CN¥4.73 Billion | +9.89% |
| 2015-12-31 | CN¥4.30 Billion | +3.60% |
| 2014-12-31 | CN¥4.15 Billion | +21.06% |
| 2013-12-31 | CN¥3.43 Billion | +9.84% |
| 2012-12-31 | CN¥3.12 Billion | +21.05% |
| 2011-12-31 | CN¥2.58 Billion | +29.88% |
| 2010-12-31 | CN¥1.99 Billion | +37.50% |
| 2009-12-31 | CN¥1.45 Billion | +10.29% |
| 2008-12-31 | CN¥1.31 Billion | +27.02% |
| 2007-12-31 | CN¥1.03 Billion | +10.22% |
| 2006-12-31 | CN¥936.11 Million | -5.49% |
| 2005-12-31 | CN¥990.51 Million | +26.18% |
| 2004-12-31 | CN¥784.98 Million | +0.84% |
| 2003-12-31 | CN¥778.43 Million | +82.70% |
| 2002-12-31 | CN¥426.07 Million | +140.01% |
| 2001-12-31 | CN¥177.52 Million | +0.91% |
| 2000-12-31 | CN¥175.93 Million | +13.22% |
| 1999-12-31 | CN¥155.38 Million | -- |